176 related articles for article (PubMed ID: 26237402)
1. Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention.
Chen JJ; Chan P; Paes B; Mitchell I; Li A; Lanctôt KL;
PLoS One; 2015; 10(8):e0134711. PubMed ID: 26237402
[TBL] [Abstract][Full Text] [Related]
2. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017.
Kim D; Saleem M; Paes B; Mitchell I; Lanctôt KL
Clin Infect Dis; 2019 Aug; 69(6):980-986. PubMed ID: 30517603
[TBL] [Abstract][Full Text] [Related]
3. Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
Bjornson C; Chan P; Li A; Paes B; Lanctôt KL; Mitchell I
Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1113-1118. PubMed ID: 29557081
[TBL] [Abstract][Full Text] [Related]
4. First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).
Wang DY; Li A; Paes B; Mitchell I; Lanctôt KL;
Eur J Pediatr; 2017 Mar; 176(3):413-422. PubMed ID: 28105526
[TBL] [Abstract][Full Text] [Related]
5. Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children: Outcomes From the Canadian RSV Evaluation Study of Palivizumab Registry Over Twelve Seasons (2005-2017).
Paes BA; Saleem M; Li A; Lanctôt KL; Mitchell I;
Pediatr Infect Dis J; 2020 Jun; 39(6):539-545. PubMed ID: 32235248
[TBL] [Abstract][Full Text] [Related]
6. Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab.
Wang DY; Saleem M; Paes BA; Mitchell I; Li A; Lanctôt KL;
Pediatr Infect Dis J; 2019 Aug; 38(8):775-780. PubMed ID: 30985509
[TBL] [Abstract][Full Text] [Related]
7. Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005-2016).
Mitchell I; Wong SK; Paes B; Ruff M; Bjornson C; Li A; Lanctôt KL;
Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1345-1352. PubMed ID: 29728782
[TBL] [Abstract][Full Text] [Related]
8. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab.
Chan P; Li A; Paes B; Abraha H; Mitchell I; Lanctôt KL;
Pediatr Infect Dis J; 2015 Dec; 34(12):e290-7. PubMed ID: 26780032
[TBL] [Abstract][Full Text] [Related]
9. Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders.
Paes B; Kim D; Saleem M; Wong S; Mitchell I; Lanctot KL;
Eur J Pediatr; 2019 Mar; 178(3):377-385. PubMed ID: 30610419
[TBL] [Abstract][Full Text] [Related]
10. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
11. Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab.
Paes B; Saleem M; Kim D; Lanctôt KL; Mitchell I
Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1561-1568. PubMed ID: 31119575
[TBL] [Abstract][Full Text] [Related]
12. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
13. One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America.
Castillo LM; Bugarin G; Arias JC; Barajas Rangel JI; Serra ME; Vain N
J Pediatr (Rio J); 2017; 93(5):467-474. PubMed ID: 28236418
[TBL] [Abstract][Full Text] [Related]
14. A Comparison of Respiratory Syncytial Viral Prophylaxis in Multiple Births versus Singletons in the Canadian Registry of Palivizumab.
Paes B; Li A; Kim D; Lanctot KL; Mitchell I;
Am J Perinatol; 2021 Aug; 38(S 01):e129-e136. PubMed ID: 32232817
[TBL] [Abstract][Full Text] [Related]
15. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
Lacaze-Masmonteil T; Rozé JC; Fauroux B;
Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
[TBL] [Abstract][Full Text] [Related]
16. Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005-2015).
Li A; Wang DY; Lanctôt KL; Mitchell I; Paes BA;
Pediatr Infect Dis J; 2017 May; 36(5):445-450. PubMed ID: 28403044
[TBL] [Abstract][Full Text] [Related]
17. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
18. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.
Krilov LR; Masaquel AS; Weiner LB; Smith DM; Wade SW; Mahadevia PJ
BMC Pediatr; 2014 Oct; 14():261. PubMed ID: 25308481
[TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study.
Yi H; Lanctôt KL; Bont L; Bloemers BL; Weijerman M; Broers C; Li A; Kiss A; Mitchell I; Paes B;
Pediatrics; 2014 Jun; 133(6):1031-7. PubMed ID: 24799541
[TBL] [Abstract][Full Text] [Related]
20. Palivizumab use in infants with Down syndrome-report from the German Synagis™ Registry 2009-2016.
Simon A; Gehrmann S; Wagenpfeil G; Wagenpfeil S
Eur J Pediatr; 2018 Jun; 177(6):903-911. PubMed ID: 29651734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
